Public Release: 

8 in 10 Indonesian children has been infected with dengue

PLOS

IMAGE

IMAGE: This photograph depicted a female Aedes aegypti mosquito while she was in the process of acquiring a blood meal from her human host, who in this instance, was actually the... view more 

Credit: James Gathany, Prof. Frank Hadley Collins, Dir., Cntr. for Global Health and Infectious Diseases, Univ. of Notre Dame

Indonesia has one of the highest burdens of dengue fever, a mosquito-borne virus, in the world, and children account for many cases. Well over half of all children in urban areas are infected with dengue by the age of 5, and more than 80 percent have been infected with the virus at least once by age 10, researchers now report in PLOS Neglected Tropical Diseases.

Dengue is transmitted to people through the bites of infected Aedes mosquitoes. Symptoms can range from a fever, rash, and headache to severe bleeding in dengue hemorrhagic fever. Infection from one serotype does not provide immunity to the other three serotypes and individuals may be affected with dengue more than once. While fatality rates are less than 1 percent in most countries, overall dengue incidence is on the rise, leading to an increase in deaths from the virus worldwide. An understanding of who is infected with dengue is critical to public health planning for the disease.

This new study was designed to represent the entire Indonesian urban pediatric population. Led by Prof. Sri Rezeki Hadinegoro from the Faculty of Medicine, Universitas Indonesia, in partnership with Sanofi Pasteur, researchers collected blood samples from 3,194 children aged 1 through 18 years who lived in 30 different urban neighborhoods. Each blood sample was tested for antibodies to dengue, an indication that someone has been infected with the virus in the past. Questionnaires were also administered to determine information about each child's household demographics.

The researchers found that 69.4% of all children tested positive for dengue antibodies; 33.8% of 1-4 year olds; 65.4% of 5-9 year olds; 83.1% of 10-14 year olds; and 89.0% of 15-18 year olds. The median age to become infected with dengue for the first time was 4.8 years, and the researchers calculated that on average, 13.1% of children get their first dengue infection each year. In addition, the more people in a household who had been diagnosed with dengue since a child's birth, the more likely children were to test positive for dengue antibodies.

"The observation that 13.1% of children suffer a primary infection per year translates into many millions of infections a year. Adults are presumably infected with a similar frequency," the researchers say. "While a modelling approach would be required to quantify this burden, these data are strongly suggestive that dengue infections result in a significant burden of symptomatic and severe disease in urban Indonesia."

###

In your coverage please use this URL to provide access to the freely available article in PLOS Neglected Tropical Diseases: http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005621

Citation: Prayitno A, Taurel A-F, Nealon J, Satari HI, Karyanti MR, Sekartini R, et al. (2017) Dengue seroprevalence and force of primary infection in a representative population of urban dwelling Indonesian children. PLoS Negl Trop Dis 11(6): e0005621. https://doi.org/10.1371/journal.pntd.0005621

Funding: This work was supported by Sanofi Pasteur. The sponsor participated in the study design, data collection and analysis, decision to publish, and preparation of the manuscript. The interpretation of the data and the opinions expressed in the manuscript are those of the authors. Manuscript editing, assistance and support for the submission were provided by inScience Communications, Springer Healthcare, funded by Sanofi Pasteur.

Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: Ari Prayitno, Hindra Irawan Satari, Mulya Rahma Karyanti, Rini Sekartini, Soedjatmiko Soedjatmiko, Hartono Gunardi, Bernie Endyarni Medise, R. Tedjo Sasmono, Sri Rezeki Hadinegoro have been clinical trial and/or study investigators for, and received associated payments from, Sanofi Pasteur; Anne-Frieda Taurel, Joshua Nealon, James Mark Simmerman and Alain Bouckenooghe are employees of Sanofi Pasteur.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.